Natixis’s Krystal Biotech KRYS Stock Holding History

Natixis’s Portfolio KRYS Stock Details KRYS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-1,736	Closed	-$448K	–	1280
2026 Q1	$448K	Sell	1,736 -1,184	-41%	-$315K	﹤0.01%	826
2025 Q4	$720K	Buy	2,920 +2,798	+2,293%	+$589K	﹤0.01%	779
2025 Q3	$21.5K	Buy	+122	New	+$18.3K	﹤0.01%	964
2023 Q1	–	Sell	-4,000	Closed	-$317K	–	1099
2022 Q4	$317K	Buy	+4,000	New	+$297K	﹤0.01%	770

Other funds holding KRYS

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

SCM

Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Natixis's KRYS Position: Q2 2026 in Review

Natixis sold out of Krystal Biotech (KRYS) in Q2 2026, closing a stake of 1,736 shares — an estimated $448K sold.

Natixis first reported a position in KRYS in Q4 2022 and held it in 4 quarters. The position peaked at $720K in Q4 2025. 423 funds tracked by Wall St. Rank hold KRYS as of Q2 2026.

Natixis reported no remaining Krystal Biotech position as of Q2 2026 after selling out during the quarter.
Natixis sold 1,736 Krystal Biotech shares in Q2 2026, an estimated $448K.
Natixis first reported a position in Krystal Biotech in Q4 2022 and held it in 4 quarters.
Natixis's Krystal Biotech position peaked at $720K in Q4 2025.
423 funds tracked by Wall St. Rank held Krystal Biotech as of Q2 2026.

Based on Natixis's 13F filing for Q2 2026, filed 13 Aug 2026.